SVF Pauling (Cayman) Files to Sell 6M Shares of Relay Therapeutics (~$123M)
RLAY has more than doubled off its 52-week low of $3.445.
Summary
SVF Pauling (Cayman) Ltd filed to sell 6 million shares of Relay Therapeutics (~$123.4M), the largest single Form 144 in the 90-day window and the first by this SoftBank-affiliated stockholder.
Key Events · Ownership and Investor Activity · RLAY
-
6M Share Sale Filed by SVF Pauling
SVF Pauling (Cayman) Ltd filed a Form 144 to sell 6,000,000 shares of Relay Therapeutics, valued at approximately $123.4 million.
-
Largest Single 144 in 90 Days
This is the largest single Form 144 filing in the 90-day window and the first by this filer, adding to $8.48M in open-market insider sales over the same period.
-
~2.7% of Shares Outstanding
The 6 million shares represent roughly 2.7% of the 219.1 million shares outstanding, a meaningful overhang for the stock.
-
Long-Term Holder Exiting
Shares were acquired in July 2020 via conversion of Series C Preferred at the IPO, with original cash payment in December 2018 — a long-term institutional position being monetized.
Analysis · RLAY · Life Sciences
A SoftBank-affiliated stockholder, SVF Pauling (Cayman) Ltd, has filed a Form 144 to sell 6,000,000 shares of Relay Therapeutics, worth approximately $123.4 million at the stated market value. This is the largest single insider-related sale filing in the 90-day window and the first by this filer. The shares trace back to a Series C preferred investment made in December 2018, converted at the July 2020 IPO. The sale represents roughly 2.7% of the 219.1 million shares outstanding. Against a backdrop of heavy insider distribution — $8.48 million in open-market sales over the past 90 days, a $213 million ATM upsize on August 6, and a sharp Q2 revenue miss — this filing adds a substantial new overhang from a long-term institutional holder.
How filings like this one have moved
In the 30 days to Aug 25, 2026, 29.6% of the 2856 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.04%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RLAY was trading at $19.88 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.5B. The 52-week trading range was $3.44 to $21.27. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.